Nathan Alder, along with collaborator Doron Rapaport from the University of Tübingen (Germany), has received an award from the Reinhard-Frank Foundation for research on mitochondria-targeted bioactive compounds. Support from this foundation is designed to advance novel research that builds upon existing research strengths and promotes sustained partnership between participating institutions. The supported research will explore how some small molecules with strong therapeutic potential for treating mitochondrial disorders may function at the outer membrane of the mitochondrion, combining Alder’s expertise in the analysis of mitochondria-targeted compounds with Rapaport’s expertise in the biogenesis of mitochondrial proteins. This funding will support joint research activities in the Alder and Rapaport labs as well as reciprocal institutional visits and training opportunities for lab personnel.
Nathan Alder and Eric May have been awarded an R01 grant from the NIH National Heart, Lung and Blood Institute (NHLBI) as co-investigators on a project led by Steve Claypool at the Johns Hopkins University School of Medicine. The project, entitled “An intimate and multifaceted partnership: cardiolipin and the mitochondrial ADP/ATP carrier” (R01HL165729), is a four-year award, with a total award amount exceeding $2 million. This project will use multidisciplinary approaches for understanding the functional interactions between the ADP/ATP carrier (AAC) of the mitochondrial inner membrane and cardiolipin, the signature phospholipid of the mitochondrion. Following up on recent research progress from the Claypool group, the work supported by this grant will elucidate how cardiolipin regulates AAC folding as well as higher-order assembly of AAC with the respiratory chain supercomplex, both of which are essential for mitochondrial energy metabolism. The labs at MCB will make complementary contributions to the work, using biophysical techniques with mitochondrial and reductionist model systems (Alder Lab) and computational approaches to address dynamic AAC-lipid interactions (May Lab). A key objective of this research is to elucidate the molecular basis of disease-associated defects in AAC-cardiolipin interactions that may arise from alterations in lipid metabolism and heritable mutations in the AAC transporter. These insights will inform current models of AAC regulation and the role of AAC-lipid interactions in mitochondrial diseases.
New head of the Department of Molecular and Cell Biology explains the complexities of the evolving field — and why well-trained scientists are in high demand. Read full article in UConn Today
“Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds”
The Department of Molecular and Cell Biology would like to congratulate Dr. Carol Teschke for her recent election to the Connecticut Academy of Science and Engineering (CASE) Continue reading
Dr. Eric May’s Research Highlighted in UConn Today UConn Today, April 23, 2021, Kim Krieger, UConn Communications
James Cole is among five UConn researchers awarded internal funding to support researchers who are using their expertise to find new solutions to address the Covid-10 pandemic The program will award up to $50,000 to recipients.
Dr. James Cole received $43,439, Targeting the Endoribonuclease of Coronaviruses, Co-PIs: Mark Peczuh, Chemistry
Graduate Program in Genetics and Genomics
Department of Molecular and Cell Biology
University of Connecticut
Related Proposal for the Doctoral Degree
B.S. University of New Haven, 2017
Characterizing Synphilin-1 in proteostasis and
Thursday, July 30th, 2020
Webex Virtual Seminar
Major Advisor: Dr. Kenneth Campellone
Associate Advisor: Dr. Barbara Mellone
Associate Advisor: Dr. Leighton Core
Examiner: Dr. Aoife Heaslip
Examiner: Dr. David Goldhamer
Researchers Explore Potential Treatment for Mitochondrial Diseases
UConn researchers are studying a group of compounds that could protect mitochondria in ways that might prevent devastating illnesses like muscular dystrophy and ALS.
Huntington’s. Parkinson’s. Muscular dystrophy. Lou Gehrig’s. These diseases share a common cause that devastatingly robs sufferers of their energy, muscle control, and in the case of Huntington’s, their sanity. But now, a group of researchers from UConn describes how a possible therapy might work.
What all those fearsome diseases have in common is dysfunctional mitochondria. Mitochondria are the body’s tiny power plants. These minuscule, rod-shaped structures inside our cells take in oxygen and nutrients and put out ATP, the body’s fuel (ATP is to cells what gasoline is to cars.) When mitochondria don’t work so well, the dysfunction can cause strange and awful symptoms that are particularly distressing in parts of the body that require lots of energy: particularly muscles, the brain, and nerve tissue.
Mitochondrial diseases tend to worsen with age. Scientists have guessed that mitochondria age as the rest of our body does. Damage acquired over time may contribute to mitochondrial diseases, but they aren’t entirely sure what’s happening or how to stop it.
“They’re insidious diseases because they rob your cells of their energy. They’re so hard to diagnose and the symptoms can be so diverse,” says Nathan Alder, a molecular biophysicist in the Department of Molecular and Cell Biology at UConn.
Alder and other researchers from UConn, the University of Texas, and Alexandria LaunchLabs are researching a group of compounds that seem to protect and even repair damage to mitochondria. The researchers describe the compounds, called SS peptides, and one potential way they may work to heal mitochondria in an upcoming issue of the Journal of Biological Chemistry.
SS peptides are made of amino acids, the building blocks of proteins, but each SS peptide is only four amino acids long. They all have the same basic plan: two amino acids with a positive charge alternating with two aromatic amino acids (“aromatic” is a chemistry term meaning they have a ring-like structure similar to benzene).
Previous research by Hazel Szeto at Cornell University, who first described SS peptides and served as co-author on this study, showed that SS peptides can enter into any cell in the body, and mitochondria suck them up like sponges. Alder and his colleagues wanted to figure out what the peptides were doing when they got in there. Using approaches ranging from computer modeling to studying mitochondria in the lab, they began to see the peptides’ effects. It looks like they can alter and potentially repair mitochondria by tuning the electric properties of their membranes.
Mitochondrial membranes are intricately creviced double-layers of fatty molecules called lipids that surround proteins sticking out of the membrane itself. The outer layer of the membrane “talks” to the rest of the cell, sensing conditions and passing ATP and other molecules back and forth. The labyrinthine inner layer of the membrane holds the ATP factories. One of the special lipids enriched in the inner membrane, cardiolipin, has a strong affinity for SS peptides.
Mitochondria tend to accumulate positively charged things like calcium ions—mitochondria actually serve as storage centers for cellular calcium. Yet calcium overload can cause damage to mitochondria’s cardiolipin-containing membranes over time, ripping into the membrane and causing permanent damage.
SS peptides can prevent that from happening, Alder and his colleagues found. The peptides are positively charged but in a gentler way than calcium; they snuggle up against the mitochondrial membrane and shield it from the smaller, more damaging calcium ions.
“This is probably not the only effect of SS peptides. But it’s an interesting one,” Alder says. The researchers want to understand more about how the peptides interact with the mitochondria and why they appear to have such broad-based efficacy against so many mitochondrial disorders. The team is currently using UConn’s nuclear magnetic resonance facilities to get detailed pictures of SS peptide structural features and how the peptides might alter or maintain the shape of the mitochondrial membranes. “We know they work. We want to know how they work. By understanding the mechanism of action, we can engineer more effective peptide analogs and possibly tailor them to treat specific mitochondrial afflictions,” Alder says.
Structural Biology, Biochemistry and Biophysics
Department of Molecular and Cell Biology
University of Connecticut Announces the
Related Proposal for the Doctoral Degree
Stephen Hesler, B.S. Lehigh University, 2011
Reevaluating the Activation Model of PKR
Thursday, October 31, 2019
Major Advisor: Dr. James L. Cole
Associate Advisor: Dr. Carolyn Teschke
Associate Advisor: Dr. Victoria Robinson
Associate Advisor: Dr. Eric May
Associate Advisor: Dr. Debra Kendall